MA-EDB
9.12.2021 15:02:04 CET | Business Wire | Press release
EDB , an open source innovator and the leading contributor to PostgreSQL®, announced today the worldwide immediate availability of EDB 14, its premiere PostgreSQL platform. EDB® 14 adds critical enterprise capabilities, including extreme high availability and multi-master replication, which are necessary for running today’s mission-critical applications, whether high-speed transactional systems in financial services or geo-distributed analytical systems in retail. Further improvements to EDB’s powerful Oracle database compatibility technology enable even smoother migration, which is essential for the growing number of organizations moving to the cloud.
“Postgres is the fastest growing database platform worldwide with rapid adoption by developers and enterprises," Marc Linster, CTO, EDB. "With EDB 14, we've pushed Postgres even further to support our customers’ most demanding workloads and help them migrate faster at a lower total cost of ownership. This release offers even more incentive for businesses to move away from traditional databases and get onto Postgres now, or get more from it if they’re already there."
EDB 14 highlights
With the largest team of PostgreSQL engineers of any other software vendor, EDB continues to strengthen PostgreSQL to help enterprises do more and go faster. Highlights include:
- Extreme high availability : Postgres-BDR®, a component of the EDB 14 release, allows customers to run PostgreSQL with 99.999% availability through its innovative multi-master replication capability, a feature no other PostgreSQL database offers. Multi-master replication allows customers to operate their PostgreSQL databases in “Always On” architectures with zero downtime updates and upgrades, which is critical for keeping their databases running optimally and securely.
- Enhanced Oracle database compatibility : EDB Postgres Advanced ServerTM adds features that further improve compatibility with Oracle database technology. This capability is vital for customers looking to move applications or data from Oracle database to PostgreSQL and benefit from its superior usability and reduced operational and licensing costs.
- Improved DevOps for PostgreSQL : EDB’s Cloud Native PostgreSQL, another component of EDB 14, helps Kubernetes users take full advantage of PostgreSQL as their database of choice. This latest version of Cloud Native PostgreSQL provides connection pooling to enable workloads with many concurrent connections to run in Kubernetes, supporting applications with even higher user demands than before.
- Deployment flexibility : PostgreSQL customers can deploy EDB 14 in any manner, including using EDB’s BigAnimalTM , the first fully managed PostgreSQL database in the cloud with compatibility for Oracle database technology, or self-manage their database on premises.
- Choice of PostgreSQL distributions : The EDB 14 platform has been tested with PostgreSQL 14 and EDB Postgres Advanced Server 14, enabling customers to choose between PostgreSQL distributions and tools, including open source, EDB, or a combination.
To learn more about EDB 14, visit the EDB blog . For details about BigAnimal and to sign up for a free trial, visit www.BigAnimal.com .
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres is a trademark of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
Oracle, Java, and MySQL are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom